-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$22.00349.9% Upside
INmune Bio, Inc. Frequently Asked Questions
-
What analysts cover INmune Bio, Inc.?
INmune Bio, Inc. has been rated by research analysts at Scotiabank in the past 90 days.